Quest Diagnostics (DGX) opened Q1 2026 with total revenue of US$2.9 billion and basic EPS of US$2.29, setting the tone for how the new year is starting to shape up for the testing giant. Over recent quarters the company has seen revenue move from US$2.6 billion in Q1 2025 to US$2.9 billion in Q1 2026, while basic EPS shifted from US$1.97 to US$2.29. This gives investors a clear view of how the top and bottom lines are tracking through the most recent reporting stretch. With a trailing twelve month net profit margin sitting at 9% and earnings growth cited ahead of the multi year trend, this update puts profitability at the center of the conversation around the latest results.

See our full analysis for Quest Diagnostics.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the prevailing stories about Quest Diagnostics, and where those narratives might need a rethink based on the recent margin and earnings trends.

TTM earnings of US$1.0b put profitability in focus

• Over the last twelve months, Quest Diagnostics generated US$1.0b in net income on US$11.3b of revenue, with a 9% net margin compared with 8.8% a year earlier.
• Analysts' consensus view that higher test volumes and richer test mixes can support margin strength is partly backed by this 9% margin,
  • Consensus highlights growth in advanced and preventive testing as a key driver, and the move from 8.8% to 9% margins fits with the idea that higher value testing is contributing more to profits.
  • At the same time, revenue growth of 4% per year that trails the cited 10.9% US market rate reminds you that margin gains are doing more of the work than top line expansion.

Earnings up 14.3% while five year trend is still weak

• Trailing twelve month earnings growth of 14.3% contrasts with a five year average earnings decline of 20.3% per year, and Q1 2026 net income of US$252 million compares with US$219 million in Q1 2025.
• What stands out for the bullish narrative is that this recent 14.3% earnings growth aligns with expectations for profit improvement,
  • Bulls point to automation, AI and cost efficiencies as drivers, and the step up from US$892 million in TTM net income at Q1 2025 to US$1.0b at Q1 2026 is consistent with that story.
  • Yet the five year record of earnings decline means this one year rebound needs to be viewed alongside a longer stretch where profit trends were less favorable.

On these numbers, bulls may see early confirmation that operational changes are feeding through to profit, but the mixed history means it can be useful to see how the full optimistic case fits together in more detail 🐂 Quest Diagnostics Bull Case.

P/E of 22.2x and DCF fair value gap draw attention

• With a P/E of 22.2x at a share price of US$205.04, Quest Diagnostics is priced below the US Healthcare industry average P/E of 23.6x and the cited peer average of 36.8x, and the DCF fair value of US$307.34 sits well above the current price alongside a 1.68% dividend yield.
• Bears focus on risks like higher debt and reimbursement pressure, and these concerns sit against valuation metrics that point to potential upside,
  • The data shows the stock trading about 33.3% below the DCF fair value of US$307.34, which challenges a purely cautious stance that sees limited room for upside at current levels.
  • On the other hand, the flag on a high debt load and a five year earnings decline of 20.3% per year gives skeptics concrete reasons to question how smooth any future earnings path might be.

For readers weighing those downside risks against a P/E discount and the DCF fair value gap, it can help to see how a more cautious case frames the same numbers 🐻 Quest Diagnostics Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Quest Diagnostics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between recent earnings momentum and a mixed longer term record, it makes sense to look through the numbers yourself and move quickly while the picture is still fresh. To weigh both sides of the story in one place, start by reviewing the 4 key rewards and 1 important warning sign

See What Else Is Out There

Quest Diagnostics combines a 9% margin and recent earnings growth with a weak five year earnings record, higher debt and ongoing reimbursement concerns.

If that mix of profit progress and balance sheet risk gives you pause, compare it with companies highlighted in the 72 resilient stocks with low risk scores to quickly spot potentially steadier options.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.